Literature DB >> 4007251

Pharmacokinetics and bioavailability of pinacidil capsules in human volunteers.

M S Laher, M P Hickey.   

Abstract

Pinacidil is a new and potent vasodilator, which has recently been used in the treatment of various forms of hypertension. In this study pharmacokinetic parameters were determined following administration of intravenous (0.2 mg/kg) and capsule (12.5 mg) formulations of pinacidil to twelve healthy volunteers. The serum half-life (t1/2) and volume of distribution (Vd) of pinacidil were 2.04 +/- 0.40 h and 1.4 +/- 0.4 l/kg respectively, while the elimination rate constant (k el) was 0.34 +/- 0.07 h-1. The mean bioavailability of pinacidil (capsule formulation) was 57% +/- 16 S.D. Mild side-effects such as dizziness, headache and fatigue were noted in two volunteers following intravenous administration of pinacidil, while no side-effects were reported with the oral formulation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4007251     DOI: 10.1177/030006058501300302

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  4 in total

Review 1.  Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  H A Friedel; R N Brogden
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

Review 2.  Pinacidil. Preclinical investigations.

Authors:  I Ahnfelt-Rønne
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Pharmacodynamic model of the haemodynamic effects of pinacidil in normotensive volunteers.

Authors:  P Girard; J L Saumet; F Dubois; J P Boissel
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  The KATP channel in migraine pathophysiology: a novel therapeutic target for migraine.

Authors:  Mohammad Al-Mahdi Al-Karagholi; Jakob Møller Hansen; Johanne Severinsen; Inger Jansen-Olesen; Messoud Ashina
Journal:  J Headache Pain       Date:  2017-08-23       Impact factor: 7.277

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.